Back to Search
Start Over
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
- Source :
- Pharmacogenomics. 18:35-56
- Publication Year :
- 2017
- Publisher :
- Future Medicine Ltd, 2017.
-
Abstract
- Aim: The present study aimed to conduct a series of meta-analyses to investigate the influence of imatinib trough concentration (C0), as well as ABCB1 and ABCG2 polymorphisms, on the clinical response in patients with chronic myeloid leukemia (CML). Methods: A literature search was conducted using the PubMed and Cochrane electronic databases to locate relevant papers from 2003 onward. Then, an initial meta-analysis of 14 studies involving 2184 patients was conducted to understand the effect of imatinib mesylate (IM) C0 on clinical outcome in CML patients. Subsequently, a series of meta-analyses were performed, including up to 23 studies with 2577 patients, on the effect of genetic polymorphisms of ABCB1 and ABCG2 on the clinical response to IM. Results: Meta-analysis revealed that patients who achieved a major molecular response (MMR) have a significantly higher IM C0 than those who failed to achieve an MMR. We also found that the patients who achieved a complete cytogenic response (CCyR) have a significantly higher IM C0 than those who did not achieve a CCyR. However, no significant difference in IM C0 was found between the complete molecular response and non-complete molecular response groups. Additional analysis showed that ABCG2 421 variant A allele was significantly associated with a higher rate of MMR and overall response, especially in Asian patients. Meta-analysis did not reveal a correlation between ABCB1 C3435T and C1236T polymorphisms with any clinical response to IM. However, the G2677T/A polymorphism could play a role in IM response in the recessive model. Conclusion: This meta-analysis demonstrates that there was a significant correlation between the IM trough concentration and clinical responses, especially MMR and CCyR, in CML patients. Furthermore, we found that the probability of successful treatment was correlated with the ABCG2 C421A polymorphism, at least within the Asian population. We failed to determine an association between ABCB1 polymorphisms and IM response, although the G2677T/A polymorphism might be involved. However, further large-scale investigations using more sensitive genotyping methods would be required to confirm this.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Abcg2
ABCG2
Antineoplastic Agents
clinical response
Polymorphism, Single Nucleotide
meta-analysi
polymorphism
03 medical and health sciences
0302 clinical medicine
trough concentration
Genetic
Asian People
Predictive Value of Tests
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Internal medicine
Genetics
medicine
ATP Binding Cassette Transporter, Subfamily G, Member 2
Humans
Trough Concentration
In patient
Pharmacology
biology
business.industry
Myeloid leukemia
ABCB1
Imatinib
Neoplasm Proteins
Treatment Outcome
030104 developmental biology
Imatinib mesylate
imatinib
030220 oncology & carcinogenesis
Major Molecular Response
Meta-analysis
Immunology
Imatinib Mesylate
biology.protein
Molecular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 17448042 and 14622416
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Pharmacogenomics
- Accession number :
- edsair.doi.dedup.....93c43d241d4e78b8e7895ff092e08988
- Full Text :
- https://doi.org/10.2217/pgs-2016-0103